Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Samuel MakarProf of Pediatrics and Pediatric
Nephrology , Cairo University
PATHOPHYSIOLOGY OF
HYPERTENSION
SCOPE
• Introduction
• Definition
• BP Measuring
• Types
• Pathophysiology Overview
• Pathophysiology of Specific HTN Diseases
INTRODUCTION
• There is increasing evidence that HTN has its antecedents
during childhood and that atherosclerosis is already present
in adolescents. Thus, early detection and intervention are
crucial.
• The prevalence of primary HTN is increasing among school
children and adolescents due to an epidemic of obesity.
• Younger children are more likely to have secondary HTN,
• The definition of HTN as well as normative values of blood
pressure (BP) should be well known to clinicians in order to
identify HTN
SCOPE
• Introduction
• Definition
• BP Measuring
• Types
• Pathophysiology Overview
• Pathophysiology of Specific HTN Diseases
HTN DEFINITION
• Definition of Pediatric HTN:
Average SBP and/or DBP ≥ 95th percentile
- gender, age, and height
-on 3 or more separate occasions.
• Pre-HTN :
BP levels ≥ 90th percentile but < 95th percentile is
termed prehypertension.
BP MEASURING
• Casual Blood Pressure
• Ambulatory BP monitoring (ABPM)
• Home BP monitoring (HBPM)
AMBULATORY BP MONITORING (ABPM)
• Provides multiple readings over time enabling computation of
the mean, daytime, and nighttime ambulatory BP (ABP) by
measuring BP during regular activities and BP variability
• More reliable and reproducible than casual BP
• Detects white coat effect (high casual BP than 24-h or daytime
ABP) or reversed white coat effect (low casual BP than 24-h
or daytime ABP)
• ABPM correlates better with target organ damage than casual
BP
HOME BP
• Self measurement of BP has the following advantages:
1. Distinguishing sustained HTN from white coat HTN(WCH)
2. Detection of masked HTN
3. Assessing response to medication,
4. Improving patient adherence to treatment
5. Reducing costs by avoiding ABPM or drug therapy.
Midori Awazu, Pedatric Nephrology Textbook 2016
IV Diretriz Brasileira de Hipertensão Arterial. Arq Bras Cardiol 2004
IV Guideline for Ambulatory Blood Pressure Monitoring , Arq. Bras. Cardiol, 2005
TYPES OF HTN
According to the cause:
• Primary HTN
• Secondary HTN
According to the setting
• White coat HTN
• Reversed white coat HTN
• Persistent HTN
WHITE COAT HTN (WCH)• In Children : BP measured in a physician’s office >95th percentile
whereas average BP being <90th percentile outside of a clinical setting.
• Adults : in the office (equal to or higher than 140/90 mmHg) and by 24-hour ABPM (lower than 130/80 mmHg) or by HBPM (lower than 135/85 mmHg)
(National High Blood Pressure Education Program Working Group on High Blood
Pressure in Children and Adolescents, Pediatrics, 2004)
WHITE COAT HTN (WCH)
• In WCH casual BP is high, while the BP during ABPM is normal
• WCH is considered relevant when the difference is higher than 20 mmHg and 10 mmHg for systolic pressure and diastolic pressure, respectively
Myers MG et al ,Am J Hypertens 1999
REVERSE WHITE COAT HYPERTENSION
(MASKED HTN)
• “Reverse WCH” or “WC normotension ” or Masked HTN (MA)
• MH, a high Ambulatory BP in the presence of normal office BP
• Recognized as a risk factor for cardiovascular complications in
the adults
Pickering TG et al , Hypertension 2002
• High prevalence of MH in renal transplant, CKD, obesity, sickle-
cell disease, repaired coarctation of aorta, obstructive sleep
apnea, a parental history of HTN, increased BMI, and
prehypertension
Lurbe E et al, Hypertension 2005
IV Guideline for Ambulatory Blood Pressure Monitoring , Arq. Bras. Cardiol, 2005
SCOPE
• Introduction
• Definition
• BP Measuring
• Types
• Pathophysiology Overview
• Pathophysiology of Specific HTN Diseases
Equals: Cardiac output ( CO) x
Systemic vascular resistance (SVR)
Pathophysiology Overview
SV
HR
Preload
SympNS
Remodeling
Rarefaction
StiffnessForce Exerted by
circulating blood
on artery walls
IMPORTANT KEY-PLAYERS
IN PATHOPHYSIOLOGY OF HTN
• Systemic Vascular Resistance SVR
• RAAS
• Other Important Molecules
SYSTEMIC VASCULAR RESISTANCE (SVR)
• SVR mainly a function of small, peripheral arterioles
• Cross-sectional area of a vessel decreases, resistance to flow increases
• Remodeling : Thickening of the media is the earliest structural change due
to matrix deposition, smooth muscle cell hypertrophy and hyperplasia
creating smaller lumen
• Rarefaction : Finally, there may be resorption and loss of blood vessels in
the periphery
• Stiffness: In larger vessels, the content of elastin and collagen in the
media increases, and the number of smooth muscle cells decreases leading
to a loss of elasticity
THE RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM
(RAAS)Major stimuli for secretion of Renin:
1. Glomerular underperfusion
2. Reduced sodium intake
3. Sympathetic Nervous System activity.
• Renin cleaves hepatic-derived angiotensinogen to form angiotensin I (ANG-I)
• ACE in the lungs transforms it to angiotensin II (ANG-II).
• ACE also degrades bradykinin, a potent vasodilator, into inactive metabolites.
• ANG-II is a potent vasoconstrictor and thus directly increases BP.
• It also stimulates the release of aldosterone from the zona glomerulosa of the adrenal gland, which results in a further rise in BP from aldosterone-mediated sodium and water retention..
Midori Awazu, Pedatric Nephrology Textbook 2016
Midori Awazu, Pedatric Nephrology Textbook 2016
• The functions of Ang-(1–9) are not completely understood, but Ang-(1–7) has vasodilatory and renoprotective effects
• Reduced ACE2 levels are thought to contribute to the pathogenesis of primary HTN via impaired degradation of ANG-II and reduced formation of vasodilator by-products at the level of the renal endothelium .
Stergiou GS et al, Am J Hypertens. 2008
• NB:
Primary HTN is showing more and more to be
NOT Primary HTN:
1. ACE 2 Mutation (reduced level of AT1-7)
Midori Awazu, Pedatric Nephrology Textbook 2016
ATRIAL NATRIURETIC PEPTIDE (ANP)
• Family of natriuretic peptides including B-type (BNP) and the C-
type (CNP) natriuretic peptides with similar functions
• ANP has potent diuretic,
• Natriuretic ( by inhibiting tubular sodium reabsorption and renin
and aldosterone biosynthesis )
• Vasorelaxant effects. In the kidney
• ANP increases glomerular filtration rate (GFR) through
vasodilatation of the afferent arteriole and vasoconstriction of
the efferent arteriole .
Beltowski J et al, Clin Res. 2002
ATRIAL NATRIURETIC PEPTIDE (ANP)
• Mutations in the ANP gene appear to be associated
with the development of HTN in humans
• There is also evidence that ANP gene polymorphisms may
affect the development of hypertensive sequelae
such as left ventricular hypertrophy .
Xue H et al Clin Sci (Lond). 2008
• NB:
Primary HTN is showing more and more to be
NOT Primary HTN:
1. ACE 2 Mutation (reduced level of AT1-7)
2. ANP Polymorphism
RENALASE
• Renalase is a protein composed of 342 amino is recently discovered as a new renal hormone
• Renalase degrades circulating catecholamines (primarily epinephrine) via a mechanism different than monoamine oxidase
Desir G. Pediatr Nephrol 2012
• Renalase knockout mice are hypertensive and have evidence of increased sympathetic tone, suggesting renalase may modulate SNS activity
• Recombinant renalase has been developed and appears to be a potent antihypertensive agent in experimental models .
Desir G. Pediatr Nephrol 2012
• NB:
Primary HTN is showing more and more to be NOT Primary HTN:
1. ACE 2 Mutation (reduced level of AT1-7)
2. ANP Polymorphism
3. Renalase activity
SCOPE
• Introduction
• Definition
• BP Measuring
• Types
• Pathophysiology Overview
• Pathophysiology of Specific HTN Diseases
PATHOPHYSIOLOGY OF SPECIFIC HTN
DISEASES
• Primary HTN
• Secondary HTN
SECONDARY HTN
A) Mendelian Forms of Hypertension (single-gene mutations )
• Most of the mutations found to date affect renal sodium
handling.
These disorders lead to 3 groups of diseases:
1. Aberrant distal tubular sodium reabsorption and volume
expansion due to hyperaldosteronism (Aldosterone is
increased)
2. Defects in steroid biosynthetic enzymes (causing
increased mineralocorticoid activity)
3. Activation of sodium channels or transporters (depressed
Aldosterone)
SECONDARY HTN
A) Mendelian Forms of Hypertension (single-gene mutations )
• Most of the mutations found to date affect renal sodium
handling.
These disorders lead to 3 groups of diseases:
1. Aberrant distal tubular sodium reabsorption and volume
expansion due to hyperaldosteronism (Aldosterone is
increased)
2. Defects in steroid biosynthetic enzymes (causing
increased mineralocorticoid activity)
3. Activation of sodium channels or transporters (depressed
Aldosterone)
GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM (GRA)
FAMILIAL HYPERALDOSTERONISM TYPE 1 (FH1)
• (FH-I) is AD
• Early onset of HTN with normal or elevated aldosterone
levels despite suppressed plasma renin activity
Lifton RP. Proc Natl Acad Sci U S A. 1995
• Caused by a chimeric gene that results from unequal
crossingover between the aldosterone synthase (CYP11B2)
gene and the 11β-hydroxylase
• The resulting chimeric gene (CYP11B1/CYP11B2) is expressed in the adrenal fasciculata and encodes a
protein product with aldosterone synthase enzymatic activity whose expression is regulated by ACTH.
• Consequently, aldosterone synthase activity is ectopically expressed in the adrenal fasciculata under
control of ACTH rather than by ANG-II or potassium.Aldosterone secretion becomes linked to cortisol
secretion, and maintenance of normal cortisol
• HTN is suppressed by Dexamethazone admmistration
ACTH Cortisol
Aldoster.
ACTH
Dexamethazone
Familial Hyperalsdosteronism I (GRA)
FAMILIAL HYPERALDOSTERONISM TYPE II(NON-GRA)
• Familial hyperaldosteronism type II (FH-II)
• Similar to GRA (FH-I), with excess production of mineralocorticoids, but is not suppressed by dexamethasone
• The molecular basis of the disorder remains to be determined.
FAMILIAL HYPERALDOSTERONISM TYPE III
(NON-GRA)
• Familial hyperaldosteronism type III (FH-III) recently
identified
• Mutations in the potassium channel KCNJ5
• This results in depolarization of the glomerulosa cells,
leading to increased calcium entry and aldosterone
production .
• Massive adrenal hyperplasia with refractory HTN
Geller DS, J Clin Endocrinol Metab.2008
KCNJ5 Aldoster.
Familial Hyperalsdosteronism II and III (Non-
GRA)
FIRST GROUP : FAMILIAL HYPERALDOSTERONISM
• Early onset HTN, normal or high Aldosterone
• FH -I ..Chimeric gene… GRA
• FH – II… excess production ..Not GRA
• FH-III… excess production ..Not GRA
SECONDARY HTN
A) Mendelian Forms of Hypertension (single-gene mutations )
• Most of the mutations found to date affect renal sodium
handling.
These disorders lead to 3 groups of diseases:
1. Aberrant distal tubular sodium reabsorption and volume
expansion due to hyperaldosteronism (Aldosterone is
increased)
2. Defects in steroid biosynthetic enzymes (causing
increased mineralocorticoid activity)
3. Activation of sodium channels or transporters (depressed
Aldosterone)
THE SYNDROME OF APPARENT MINERALOCORTICOID
EXCESS (AME)
• AR
• Early-onset HTN with hypokalemia and metabolic
alkalosis
• Accompanied by suppressed plasma renin activity
• And the virtual absence of circulating aldosterone.
THE SYNDROME OF APPARENT MINERALOCORTICOID
EXCESS (AME)
• Steroids other than aldosterone activate the mineralocorticoid
receptor (MR). i.e.apparent excess of MC action
• Cortisol activates MR with potency similar to aldosterone.
• Cortisol, normally, is transformed to Cortisone by 11-hydroxysteroid
dehydrogenase (11HSD) enzyme
• Mutation in the gene encoding the renal i11-hydroxysteroid
dehydrogenase (11HSD), results in impaired conversion of cortisol to
cortisone .
• In AME, the absence of this enzyme allows cortisol to activate the
MR, resulting in HTN mediated by increased sodium retention.
Mineralocorticoid Receptor
MR
AME
Cortisol
Cortisone
Cortisol
Epithelial Na channel
ENaC
Aldosterone
Cortisone
3BHSD2 3BHSD2
OTHER STEROIDS CAUSING HTN
Congenital adrenal hyperplasia results from two known defects:
1. 11-β-hydroxylase
2. 17-α-hydroxylase
SECONDARY HTN
A) Mendelian Forms of Hypertension (single-gene mutations )
• Most of the mutations found to date affect renal sodium
handling.
These disorders lead to 3 groups of diseases:
1. Aberrant distal tubular sodium reabsorption and volume
expansion due to hyperaldosteronism (Aldosterone is
increased)
2. Defects in steroid biosynthetic enzymes (causing
increased mineralocorticoid activity)
3. Activation of sodium channels or transporters (depressed
Aldosterone)
LIDDLE’S SYNDROME
• AD disorder
• Gain mutations in the epithelial Na channel (ENaC) (Amiloride
sensitive ) in the collecting ducts, which are responsible for elevated
renal sodium reabsorption in Liddle’s syndrome
• Severe HTN, metabolic alkalosis, and hypokalemia
• Low renin
• Low aldosterone.
• Unresponsive to Aldosterone antagonist (aldactone) but responsive
to amiloride and triametrene
Mineralocorticoid Receptor
MR
Liddle’s Syndrome
Na reabsorption
Epithelial Na channel
ENaC(Amiloride sensitive)
Aldosterone
Aldactone
Amiloride
triametrene
LIDDLE’S SYNDROME AND
PSEUDOHYPOALDOSTERONISM TYPE I
• In Liddle's syndrome, gain-of-function mutations in the beta or
gamma ENaC subunits have been found.
• In PHA-1, loss-of-function mutations in the alpha, beta, or
gamma subunits have been found
GORDON’S SYNDROME
(PSEUDOHYPOALDOSTERONISM TYPE II)
• The WNKs [“with no lysine”] mutations of the WNK1 and WNK4 have
been found to be responsible for Gordon ’s syndrome .
• Wild-type WNK1 and WNK4 inhibit the thiazide-sensitive Na-Cl co-
transporter in the distal tubule. Mutations of these proteins are
associated with gain of function and increased co-transporter activity,
excessive chloride and sodium reabsorption, and volume expansion.
• Increased WNK1 expression also decreases potassium excretion
by inhibiting the renal outer medullary potassium channel(ROMK).
GORDON’S SYNDROME
(PSEUDOHYPOALDOSTERONISM TYPE II)
• AD HTN
• hyperkalemia, hyperchloremic metabolic acidosis, and
normal glomerular filtration rate.
• Thiazides responsive
• This syndrome maybe associated with short stature, intellectual
impairment, dental abnormalities, muscle weakness
RENOVASCULAR HTN (RVH)
• 10%(5–25 %) of all secondary HTN in children.
• RVH is second only to coarctation of the aorta as a correctable
cause of HTN in children.
RENOVASCULAR HTN (RVH)
• Fibromuscular dysplasia (FMD ) is the most common cause of
RVH in children.
• FMD Significantly different from that in adults ( with the classic
“string of beads” in the main artery )
• FMD in children produces focal unilateral isolated web like
stenosis, and the majority of the lesions are in branch vessels or
accessory arteries.
RENOVASCULAR HTN (RVH)
Genetic syndromes such as
• NF-I
• Tuberous sclerosis
• Williams’ syndrome,
• Marfan’s syndrome,
• Turner’s syndrome
• Alagille syndrome
• Vasculitidies such as
• Takayasu’s disease, polyarteritis nodosa, Kawasaki
RENOVASCULAR HTN (RVH)
Other etiologies of RVH include
• Extrinsic compression of the renal arteries,
• Radiation,
• Umbilical artery catheterization
• Trauma
• Congenital rubella syndrome
• Aneurysms
• AVM/AVF,
• Transplant renal artery stenosis
RENOVASCULAR HTN (RVH)
• The stenosis needs to occlude at least 70%of the lumen before it
begins to reduce renal blood flow and raise arterial pressure
• In the late phase, HTN persists despite removal of the stenosis
or ischemic kidney, due to hypertensive damage to the
contralateral kidney and probably also due to systemic vascular
changes
CKD/AKI HTN
• Depends on the etiology of underlying kidney disease rather
than on the degree of renal dysfunction (children with congenital
urogenital anomalies such as renal dysplasia often do not have
HTN because of tubulopathy leading to salt and water wasting.)
• HTN resulting from renal parenchymal disease is multifactorial
in origin.
• impaired excretion of salt and water,
• reduced renal blood flow
• Activation of the RAAS
POST-RX HTN
The major contributing factors :
• History of pre-transplant HTN
• Persistent native kidney presumably via persistent release of
renin
• Effects of immunosuppressive medications
• Transplant renal artery stenosis
• Chronic allograft dysfunction
POST-RX HTN
Calcineurin inhibitors cause:
• Increased production of the vasoconstrictor endothelin
• Decreased production of vasodilatory substances
• Activation of the SNS .
• Afferent artery vasoconstriction.
• Na retention .
• Many studies suggest that calcium channel blockers can minimize
calcineurin-induced vasoconstriction thereby ameliorating HTN and
preventing chronic graft injury.
Rose C et al , Eur J Pediatr. 2001
HYPERTENSION IN ENDOCRINE DISEASES
• Pheochromocytomas and paragangliomas
• Primary hyperaldosteronism (PAL)
• Cushing’s syndrome
• Glucocorticoid-remediable aldosteronism (GRA)
• Familial hyperaldosteronism II and III
• Reninoma.
• Primary hyperparathyroidism (PHPT)
• Hyperthyroidism( activation of the RAAS and increased sodium
reabsorption )
• Diabetes mellitus (DM).
Drug Induced HTN
PRIMARY (ESSENTIAL) HTN
• Most HTN in adults has no identifiable underlying etiology;
therefore, the term “essential HTN” has been utilized for those
hypertensive individuals without underlying secondary causes.
PRIMARY (ESSENTIAL) HTN
• In children, primary HTN was traditionally considered
uncommon, accounting for less than 25 % of
hypertensive children in the early 1990s.
• However, recently the rate has increased (up to 90 % in
some USA series) mainly due to increased obesity
Din-Dzietham R et al. Circulation. 2007
Midori Awazu, Pedatric Nephrology Textbook 2016
SYMPATHETIC NERVOUS SYSTEM
ACTIVATION
Children with primary HTN :
• Resting tachycardia compared to normotensive children
• heightened cardiovascular reactivity to stress
• Elevated plasma norepinephrine levels
• NB:
Primary HTN is showing more and more to be NOT Primary HTN:
1. ACE 2 Mutation (reduced level of AT1-7)
2. ANP Polymorphism
3. Renalase activity
QUESTIONS
• Choose one correct answer :
A) Familial hyperaldosteronism type III (FH-III) has been recently identified with
mutations in the potassium channel KCNJ5 and is Glucocorticoid remediable
B) Familial Hyperaldosteronism Type I (Glucocorticoid Remediable
Aldosteronism) shows early onset of HTN with normal or elevated aldosterone
levels despite suppressed plasma renin activity
C) A chimeric gene under the effect of TSH is formed in Familial
Hyperaldosteronism Type I (Glucocorticoid Remediable Aldosteronism)
D) Cortisone causes HTN much more than Cortisol
• Choose one correct answer :
• A) Liddle’s Syndrome is an AD disease with gain of function of
Thiazide sensitive NCC in distal Tubules
• B) Gordon ‘s Syndrome is caused by a gain of function in the
Amiloride sensitive ENaC in the collecting ducts
• C) Aldactone is the drug of Choice in Liddle’s Syndrome to treat
both hypokalemia and HTN in one act
• D) Gordon’ s Syndrome shows Type IV RTA
• Choose one correct answer :
• A) Renalase maybe decreased in Primary HTN
• B) ANP polymorphism may contribute to the pathophysiology of
primary HTN
• C) ACE 2 mutations can lead to more vasoconstriction in primary HTN
• D) All of the above
In 2008,
American Heart Association issued a guideline
trying to standardize the use of ABPM in children,
including the detailed recommendations for the
use of ABPM and for the interpretation of the data
Urbina E et al . Hypertension. 2008
Subsequently, the European Society of
Hypertension recommended the use of ABPM in
children in certain settings
Lurbe E et al . J Hypertens. 2009;
functional changes specifically decreased
relaxation and increased contraction [9].
Decreased relaxation has been attributed primarily to endothelial
dysfunction,
and increased contraction has been attributed to enhanced smooth muscle cell vasoreactivity.
Sensitivity to vasoconstrictors may
also be increased.
Decreased relaxation is an effect of impaired endothelial production of vasodilatory
substances (mainly nitric oxide [NO] and prostacyclin) or increased production of
vasoconstricting substances (endothelin, platelet-derived growth factor [PDGF]), or both.
Sympathetic Innervation/CNS
Renal vessels, tubules, and the juxtaglomerular
apparatus are innervated by the renal sympathetic
nerves. Renal sympathetic nerve activity (RSNA)
influences renal hemodynamics, solute and water
handling, and hormonal release. Increased RSNA
is found in animal models of HTN and also in
hypertensive humans [13]. SNS activation, as
confirmed by increased circulating noradrenaline,
muscle sympathetic nerve traffic, and systemic
noradrenaline spillover, has for many decades
been established as almost universally present in
primary HTN
Increased RSNAconstricts the renal vasculature
and decreases GFR and renal blood flow. The
hypertensive response to chronic renal adrenergic
stimulation is associated with a sustained increase
in plasma renin activity and is dependent on an
increase in plasma angiotensin II (ANG-II) concentration
[16]. Sympathetic nerve activation appears
to enhance the response to circulatingANG-II [17].
The renal effects of ANG-II on proximal tubular
chloride and water reabsorption are decreased by
75 % in animals after experimental renal denervation.
Thus only about 25 % of ANG-II effect is
mediated directly via type 1 angiotensin receptors,
with the majority of the effect being dependent on
intact renal innervation. In experimental renal sympathetic
nerve stimulation, ANG-II enhanced the
renal venous outflow of norepinephrine, an effect
that was blocked by an ANG-II receptor antagonist
The AT2 receptor is a seven-transmembranetype,
G protein-coupled receptor comprising
363 amino acids. It has low amino acid sequence
homology (~34 %) with AT1A or AT1B receptors
[36]. The expression of the AT2 receptor is
upregulated by sodium depletion [48] and is
inhibited by ANG-II and growth factors such as
PDGF and EGF [49]. Under physiologic conditions,
the AT2 receptor mainly antagonizes
AT1-mediated actions. Cardiovascular effects of
the AT2 receptor generally appear to be opposite
to those of the AT1 receptor and may be protective
[50, 51]. In the kidney, stimulation of the AT2receptor promotes natriuresis through interactions
with the renal dopaminergic system [52].
gene
(CYP11B1) on chromosome 8. Aldosterone
synthase is the rate-limiting enzyme for aldosterone
biosynthesis in the adrenal glomerulosa, and
11β-hydroxylase is an enzyme involved in cortisol
biosynthesis in the adrenal fasciculata whose
expression is regulated by adrenocorticotropic
hormone (ACTH). The resulting chimeric gene
(CYP11B1/CYP11B2) is expressed in the adrenal
fasciculata and encodes a protein product with
aldosterone synthase enzymatic activity whose
expression is regulated by ACTH. Consequently,
aldosterone synthase activity is ectopically
expressed in the adrenal fasciculata under control
Congenital adrenal hyperplasia results from
two known defects in either 11-β-hydroxylase
or17-α-hydroxylase activity and may cause
HTN. These defects lead to overproduction of
21-hydroxylated steroids, which activate mineralocorticoid
receptors, resulting in increased
sodium reabsorption in distal tubules [295, 296].
HYPERTENSION IN ENDOCRINE DISEASES
• Pheochromocytomas and paragangliomas
• Although most pheochromocytomas are sporadic,
• there is a familial predisposition in patients
• Multiple endocrine neoplasia type II(MEN II)
• Von Hippel–Lindau disease
• NF-I and familial paraganglioma [399–401].
• Rarely, in tuberous sclerosis, Sturge–Weber syndrome, and ataxia
telangiectasia.
HYPERTENSION IN ENDOCRINE DISEASES
Primary hyperaldosteronism (PAL) is now
believed to be much more common than previously
thought [397, 412, 413].
PAL was first
reported by Conn as aldosterone-producing adenoma
(APA) [414] and commonly results from
adrenal hypertrophy (“idiopathic hyperaldosteronism”;
IHA)
Hypertension in Dialysis Patients
Children receiving chronic dialysis have a significant
incidence of HTN: 54–68 % of children
receiving hemodialysis and 50–63 % of children
receiving peritoneal dialysis in the NAPRTCS
dialysis database were receiving antihypertensive
The aldosterone/MR cascade exerts its effects in the so-called aldosterone-sensitive distal nephron (ASDN), which includes the late distal convoluted tubule, connecting tubule, and collecting duct. Upon binding of aldosterone, MR undergoes conformational changes, dissociation from chaperone proteins, dimerization, and translocation to the nucleus, where it binds to the responsive elements in the promoter regions of target genes to regulate transcription. Among the aldosterone-induced genes, serum/glucocorticoid regulated kinase 1 (SGK1) plays a major role in the control of sodium reabsorption. Studies have clarified the detailed mechanism of epithelial sodium channel (ENaC) regulation by SGK1 (Fig. 1). Nedd4-2 (neural precursor cell expressed, developmentally downregulated 4-2) is a HECT domain–containing E3 ubiquitin ligase that interacts with the C terminus of ENaC subunits and maintains the plasma membrane ENaC at low levels through ubiquitination-dependent mechanisms. Aldosterone-induced SGK1 phosphorylates the Nedd4-2, which disrupts the tonic inhibition of ENaC by Nedd4-2, leading to indirect stimulation of sodium transport. SGK1 phosphorylation of Nedd4-2 results in 14-3-3 binding and suppresses Nedd4-2–ENaCinteraction [11]. ENaC mutations in Liddle’s syndrome also affect the Nedd4-2 interaction, leading to constitutive ENaC expression and increased sodium reabsorption [12]. SGK1 may also modulate ENaC activity though a mechanism independent of Nedd4-2 [13].Fig. 1
The major pathophysiologic mechanism in
most dialysis patients seems to be volume overload
related to sodium and water retention. Evidence in
favor of fluid overload being the major mechanism
can be found in the many studies that demonstrate
correction of HTN by increased fluid removal in
both peritoneal dialysis and hemodialysis patients
[359, 360]. However, numerous other factors have
been implicated, including overactivity of the SNS,
activation of the RAAS, erythropoietin treatment,
parathyroid hormone, and nocturnal hypoxemia
[361]. Recent studies have also implicated altered
endothelial cell function, with increased vasoconstrictors
such as endothelin and a reduction of
vasodilators such as NO being involved in the
pathogenesis of dialysis HTN
POST-RX HTN
HTN is a common complication following renal
transplantation.
85% of deceased donor recipients and 79 % of live donor recipients
are receiving antihypertensive medications immediately post-transplant (decreasing to 69 %
and 59 %, respectively 5 yrs after TX) [370].
Endothelin-1Endothelin-1 (ET-1) is an endothelial-derived,
potent vasoconstrictive peptide containing
21 amino acids [110]. Three isopeptides of
endothelin (ET-1, ET-2, ET-3), encoded by separate
genes, have been identified [111]. Endothelial
ET-1 synthesis is activated by vasoactive hormones,
growth factors, hypoxia, shear stress, lipoproteins,
free radicals, endotoxin, and
cyclosporine and is inhibited by NO, natriuretic
peptides, heparin, and prostaglandins [112]. Apart
from endothelial cells, ET-1 is also produced by
•ET-1 primarily appears to be a locally acting
•paracrine substance. ET-1 closes membrane K+
•channels [115], which prevents cellular efflux of
•K+, thereby favoring membrane depolarization,
•leading to smooth muscle cell contraction. In the
•kidney, ET-1 causes constriction of both afferent
•and efferent glomerular arterioles, thereby reducing
•both renal plasma flow and glomerular filtration
•rate [116]. It blocks reabsorption of sodium
•by inhibiting tubular Na+/K+–ATPase activity in
•the proximal tubule and collecting duct [117].
•Endothelin signals through two receptor subtypes
•NO is a vasodilator, and the balance between
•NO and various endothelium-derived vasoconstrictors
•and the SNS maintains physiologic vascular
•tone [133]. In addition, NO suppresses
•platelet aggregation, leukocyte migration, and cellular
•adhesion to the endothelium. It attenuates
•vascular smooth muscle cell proliferation
•and migration, as well as inhibits activation and
•expression of certain adhesion molecules and
•has an influence on production of superoxide
•anion [134].
•Endothelium-dependent relaxation is decreased
•in patients with primary HTN [135] and appears to
•be related to defective L-arginine transport.
•Treatment
•with inhibitors of NO synthesis induces a
•hypertensive response, while L-arginine treatment
•prevents the development of HTN in salt-sensitive
•rats [137] and also causes a rapid reduction in
•systolic and diastolic pressures when infused into
•both healthy subjects and patients with primary
•HTN [138]. Methylated L-arginine derivatives,
•including NG-NG-dimethylarginine (asymmetric
•dimethylarginine, ADMA), an endogenous inhibitor
•of NOS, and symmetric dimethylarginine, its
•inactive isomer, are present in human plasma and
•urine. Elevated levels of ADMAand other markers
•of oxidative stress have been demonstrated in
•patients with primary HTN and have been postulated
•to contribute to the endothelial dysfunction
•that accompanies HTN [139].
Shibata S and Fujita T . Curr. Hypertens. Rep.2011
Shibata S and Fujita T . Curr. Hypertens. Rep.2011
UP TO DATE
• INTRODUCTION
• Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type
1 are rare genetic disorders associated with abnormalities in the function of
the collecting tubule sodium channel, also called the epithelial sodium
channel (ENaC) or the amiloride-sensitive sodium channel:
• ●ENaC function is increased in Liddle's syndrome, leading to manifestations
similar to those caused by mineralocorticoid excess, such as hypertension
and, in some patients, hypokalemia and metabolic alkalosis. Presentation at
a young age, which occurs in most patients, suggests the possibility of a
genetic disorder rather than an adrenal adenoma. In addition, plasma and
urinary aldosterone levels are reduced, not increased as in primary
aldosteronism.
• ●ENaC function is decreased in autosomal recessive
pseudohypoaldosteronism type 1, resulting in aldosterone resistance.
Affected patients present in infancy with sodium wasting, hypovolemia, and
hyperkalemia. These findings are similar to those in other forms of
hypoaldosteronism in children, except that plasma aldosterone levels are
ANG II
• Angiotensin II and angiotensin III (ANG-II, ANG-III) induce
aldosterone synthesis
• Potassium, endothelin, adrenocorticotropic hormone (ACTH)
and vasopressin stimulate its secretion .
• Inhibitors of aldosterone secretion include atrial natriuretic
peptide, somatostatin, and dopamine. Dietary sodium restriction
increases aldosterone secretion in order to restore plasma
volume.
• Aldosterone acts via type I mineralocorticoid receptors causing
retention of sodium and potassium excretion. It also activates
the SNS